ALEC Stock Summary and Trading Ideas (Alector | NASDAQ:ALEC)

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Alector trades on the NASDAQ stock market under the symbol ALEC.

As of June 9, 2026, ALEC stock price declined to $1.63 with 428,569 million shares trading.

ALEC has a beta of 2.11, meaning it tends to be more sensitive to market movements. ALEC has a correlation of 0.05 to the broad based SPY ETF.

ALEC has a market cap of $180.97 million. This is considered a Micro Cap stock.

Last quarter Alector reported $1 million in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-8 million and exceeded earnings estimates by $.08.

In the last 3 years, ALEC traded as high as $9.07 and as low as $.87.

The top ETF exchange traded funds that ALEC belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

ALEC has underperformed the market in the last year with a price return of +9.4% while the SPY ETF gained +24.3%. ALEC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.5% and -26.2%, respectively, while the SPY returned +9.9% and -1.2%, respectively.

ALEC support price is $1.55 and resistance is $1.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALEC shares will trade within this expected range on the day.